Medpace Holdings

MEDPsupplier

Medpace is a differentiated full-service CRO focused exclusively on biotech clients (not Big Pharma), with a scientific-first model and 40+ year average clinician tenure driving industry-best quality.

⇄ Compare

产品与营收

产品营收占比

营收构成 ($2.30B)

静态数据（加载实时财务…）

Net Revenue (Services) (100%)

业务板块构成与主要客户

产品详情

Full-Service CRO85%

End-to-end clinical trial management for biotech clients — Phase I-IV, regulatory, data management, biometrics.

Regulatory Consulting15%

FDA/EMA regulatory strategy, IND/NDA writing, and submission preparation.

供应链关系

主要客户

Eli Lilly and Company

Phase II/III clinical trial management

影响: moderate

Moderna, Inc.

mRNA vaccine clinical services

影响: moderate

宏观与市场背景

헬스케어行业新闻

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

近期催化剂

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

AI 分析

点击「获取 AI 分析」以获得 Medpace Holdings 的 AI 供应链分析。

企业信息

总部

Cincinnati, Ohio, USA

成立时间

1992

员工人数

5,800

官网

medpace.com

行业概况 — 헬스케어

行业新闻